Natera is a molecular diagnostics company that uses proprietary cell-free DNA technology and bioinformatics to develop blood-based and tissue tests for detecting genetic variations across oncology, women's health, and organ health. The company's product portfolio includes personalized tumor DNA monitoring tests (such as Signatera for tracking cancer mutations), non-invasive prenatal testing and carrier screening for pregnancy, and organ rejection monitoring for transplant recipients; it operates CLIA-certified laboratories and partners with over 100 distribution partners globally to deliver these tests. Natera generates revenue by processing test volumes through its own laboratories and partner networks, with tests reimbursed by Medicare, Medicaid, and commercial insurers across a broad covered population.